The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG Trial).

S. Kadowaki, D. Sakai, R. Kawabata, H. Hara, H. Yasui, M. Takahashi, M. Hirao, H. Imai, K. Minashi, T. Kawakami, H. Satake, J. Matsuyama, Y. Sakamoto, K. Sawada, M. Kataoka, H. Kawakami, T. Shimokawa, N. Boku, T. Satoh

ESMO Congress 2023, Madrid Spain 20 Oct – 24 Oct 2023